bci: a unique, guideline-recognized test to predict benefit of extended endocrine therapy
Published 5 months ago • 47 plays • Length 4:30Download video MP4
Download video MP3
Similar videos
-
2:53
bci: guideline-recognized and validated to help guide extended endocrine decisions
-
9:47
bci as a predictive biomarker for extended endocrine therapy benefit
-
0:52
the role of bci in extended endocrine therapy decision making
-
5:04
standardizing extended endocrine therapy recommendations
-
13:04
breast cancer index (bci)
-
6:35
extended endocrine therapy: who will benefit?
-
53:42
guideline updates for extended endocrine therapy decision-making in hr , early-stage breast cancer
-
1:23
brock schroeder discusses bci findings in er breast cancer
-
41:53
guideline updates for extended endocrine therapy decision-making in hr , early-stage breast cancer
-
1:43
bci case study: help avoid under-treatment with the breast cancer index test
-
1:37
the bci prognostic model for late relapse breast cancer
-
20:25
the predictive power of the breast cancer index (h/i) biomarker-sabcs 2022
-
3:04
role of advanced practitioners in extended endocrine therapy decision-making (or bci)
-
1:10:36
updates in extended endocrine therapy for hr breast cancer | asco21 & national practice guidelines
-
2:27
bci: an established tool for use in n1 patients
-
16:19
breast cancer index, extended endocrine therapy | elizabeth ott, pa | 2022 west oncology app updates
-
2:20
de-escalating n1 patients not likely to benefit from extended endocrine therapy
-
3:22
decision-making impact of the breast cancer index